Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 10:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,850 matching trials from the live ClinicalTrials.gov search.
Filters: "gene therapy" Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

The TCF7L2 Gene: Dietary Prevention of T2DM

NCT03458494
View directory record Official record
Conditions
Type2 Diabetes, Glucose, High Blood
Interventions
Mediterranean Diet, Low-fat diet
Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 1 Interventional

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

NCT03131037
View directory record Official record
Conditions
Lung Cancer
Interventions
CAN-2409 + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Results available

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 12, 2026, 10:01 AM EDT
Recruiting Phase 2 Interventional

Arginine Replacement Therapy in COVID-19

NCT05855330
View directory record Official record
Conditions
COVID-19
Interventions
Arginine Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 12, 2026, 10:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurocognitive Outcomes of Depression in the Elderly

NCT00570583
View directory record Official record
Conditions
Major Depression, Dementia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 1 Interventional

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

NCT01087294
View directory record Official record
Conditions
Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
Interventions
Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 2 Interventional

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

NCT00001145
View directory record Official record
Conditions
Immunoproliferative Disorder
Interventions
Bacteriophage, rhuCD40L, KLH
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 12, 2026, 10:01 AM EDT
Completed No phase listed Observational

Predicting Tolerance to Radiation Therapy in Older Adults With Cancer

NCT01752751
View directory record Official record
Conditions
Pre-treatment Loss of Independent Activities of Daily Living
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resistant Starch Wheat for Improved Metabolic Health

NCT03082131
View directory record Official record
Conditions
Gut Microbiota, Metabolism, Metabolic Health
Interventions
Resistant Starch Wheat
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
40 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Red Raspberry Polyphenols on Gut Microbiome

NCT03049631
View directory record Official record
Conditions
Healthy Subjects, Pre-diabetes
Interventions
Raspberry and fructooligosaccharide, Raspberry
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 12, 2026, 10:01 AM EDT
Completed No phase listed Observational Results available

Transthyretin Amyloidosis Outcome Survey (THAOS)

NCT00628745
View directory record Official record
Conditions
Transthyretin Gene Mutations, Transthyretin Amyloidosis
Interventions
None. Observational Study.
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 12, 2026, 10:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

NCT06390839
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Results available

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

NCT03293030
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
Interventions
Dupilumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 12, 2026, 10:01 AM EDT
Terminated Phase 3 Interventional Results available

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00738881
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Pemetrexed Disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
268
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Antioch, California + 176 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 12, 2026, 10:01 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

NCT01498445
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Resvida, a Comparison With Calorie Restriction Regimen

NCT00823381
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Diabetes, Aging
Interventions
resveratrol, placebo, Calorie Restriction
Dietary Supplement · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Results available

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT01687400
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 12, 2026, 10:01 AM EDT
Terminated Early Phase 1 Interventional

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

NCT04630353
View directory record Official record
Conditions
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions
HB-201 IV
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 12, 2026, 10:01 AM EDT
Not listed No phase listed Observational

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

NCT00897065
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, polymerase chain reaction, protein expression analysis, diagnostic laboratory biomarker analysis, fluorescent antibody technique, immunohistochemistry staining method, immunologic technique
Genetic · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Female only
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 12, 2026, 10:01 AM EDT
Completed No phase listed Observational

Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation

NCT01568723
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
response to therapy
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 2 Interventional

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

NCT00234741
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326 mesylate
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 12, 2026, 10:01 AM EDT
Recruiting No phase listed Observational

Duchenne Electronic Health Record Study

NCT07609394
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier
Interventions
Observational study with patients who may be treated with various disease-modifying therapies
Other
Lead sponsor
The Duchenne Registry
Other
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2072
U.S. locations
10
States / cities
Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 12, 2026, 10:01 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

NCT05778877
View directory record Official record
Conditions
Methylmalonic Acidemia (MMA)
Interventions
SEL-302
Drug
Lead sponsor
Selecta Biosciences, Inc.
Industry
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 12, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Results available

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

NCT02091141
View directory record Official record
Conditions
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
Interventions
Trastuzumab, Pertuzumab, Erlotinib, Vemurafenib, Cobimetinib, Vismodegib, Alectinib, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 12, 2026, 10:01 AM EDT